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Abstract
The early detection and endoscopic treatment of patients with the dysplastic stage of Barrett’s oesophagus is a
key to preventing progression to oesophageal adenocarcinoma. However, endoscopic surveillance protocols are
hampered by the invasiveness of repeat endoscopy, sampling bias, and a subjective histopathological diagnosis of
dysplasia. In this case-control study, we investigated the use of a non-invasive, pan-oesophageal cell-sampling
device, the CytospongeTM, coupled with a cancer hot-spot panel to identify patients with dysplastic Barrett’s
oesophagus. Formalin-fixed, paraffin-embedded (FFPE) CytospongeTM samples from 31 patients with non-
dysplastic and 28 with dysplastic Barrett’s oesophagus with good available clinical annotation were selected for
inclusion. Samples were microdissected and amplicon sequencing performed using a panel covering >2800 COS-
MIC hot-spot mutations in 50 oncogenes and tumour suppressor genes. Strict mutation criteria were determined
and duplicates were run to confirm any mutations with an allele frequency <12%. When compared with endos-
copy and biopsy as the gold standard the panel achieved a 71.4% sensitivity (95% CI 51.3–86.8) and 90.3%
(95% CI 74.3–98.0) specificity for diagnosing dysplasia. TP53 had the highest rate of mutation in 14/28 dys-
plastic samples (50%). CDKN2A was mutated in 6/28 (21.4%), ERBB2 in 3/28 (10.7%), and 5 other genes at
lower frequency. The only gene from this panel found to be mutated in the non-dysplastic cases was CDKN2A in
3/31 cases (9.7%) in keeping with its known loss early in the natural history of the disease. Hence, it is possible
to apply a multi-gene cancer hot-spot panel and next-generation sequencing to microdissected, FFPE samples
collected by the CytospongeTM, in order to distinguish non-dysplastic from dysplastic Barrett’s oesophagus. Fur-
ther work is required to maximize the panel sensitivity.
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Introduction
Barrett’s oesophagus (Barrett’s) is the precursor
lesion to oesophageal adenocarcinoma (OAC), and it
generally progresses to cancer via intermediate stages
termed low-grade dysplasia (LGD), high-grade dys-
plasia (HGD), and intramucosal carcinoma (IMC),
graded according to the severity of the cellular archi-
tecture [1]. It is a highly heterogeneous disease with
multiple genetically distinct clones identifiable within
a Barrett’s segment [2]. OAC is an aggressive cancer
with an extremely poor survival rate with <15% of
patients surviving 5 years [3]. This is largely attribut-
able to the fact that patients present in the advanced
stages of the disease. If Barrett’s is diagnosed at the
dysplastic stages, it can be treated endoscopically,
thus reducing the risk of cancer and improving sur-
vival dramatically, even when accounting for lead
time bias (>80% 5-year survival) [4]. However, there
are challenges with early diagnosis. Firstly, the
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majority of patients with Barrett’s are never diagnosed
due to the risk factors being rather common, non-
specific, and reliant on endoscopy. The main risk fac-
tors are reflux symptoms, male sex, age> 50, white
race, and obesity. The association of OAC with symp-
toms of gastro-oesophageal reflux disease (GORD)
was first demonstrated in a case-control study in 1999:
odds ratio 7.7 (95% CI 5.3–11.4). Among patients
with severe, chronic, recurrent reflux symptoms, the
odds ratio was found to be much higher at 43.5 (95%
CI 18.3–103.5). More recently, a meta-analysis has
shown that people with GORD are 2.90 (95% CI
1.86–4.54) times more likely to develop Barrett’s [5].
These results vary significantly, probably because of
the way that reflux is defined and categorized, but
reflux is clearly a risk factor. Secondly, only 0.33% of
patients with Barrett’s will progress to OAC [6]. This
poses the problem of having to survey large numbers
of patients who are at very low risk of progression.
Barrett’s is usually diagnosed when patients are
referred for evaluation of persistent reflux symptoms,
or by chance at endoscopy performed for another
purpose such as anaemia. Once diagnosed, periodic
endoscopic monitoring or surveillance is generally
recommended. Surveillance in the United Kingdom
currently involves the endoscopic sampling of the
Barrett’s segment in all four quadrants of the oeso-
phagus every 2 cm with targeted biopsy of visible
lesions [7]. Whilst this is currently considered the
gold standard, there are inherent, unavoidable prob-
lems associated with this method. Quadrantic biopsies
are unable to sample all of the mucosa, and may
potentially miss focal dysplasia, causing a sampling
error; endoscopy is invasive, uncomfortable, and time-
consuming with associated high costs. The original
Seattle protocol was very important in introducing a
systematic approach to surveillance [8]. However,
more recent studies have shown that 2 cm biopsies
may be sufficient [9] and published data show that
surveillance protocols are poorly adhered to [10,11].
To diagnose dysplasia, biopsies are fixed in forma-
lin, processed into paraffin blocks, cut into sections,
and stained with haematoxylin and eosin for patho-
logical review. However, diagnosing dysplasia can be
subjective [12–14] and inflammation can mimic the
cellular changes observed in dysplasia. There is,
therefore, a need to find ways to enhance the current
methods used to identify those individuals at
increased risk for OAC.
One such alternative to endoscopy for diagnosis
and surveillance is the CytospongeTM, a small capsu-
lar device that is swallowed and then expands to a
sponge in the stomach. As it is removed, by pulling
on a string, it collects cells from the whole of the
oesophageal epithelium. It samples all the heteroge-
neous Barrett’s clones present [2] thereby removing
the sampling bias which occurs with biopsies. Non-
dysplastic Barrett’s can be diagnosed using Trefoil
Factor Family 3 (TFF3) antibody staining on cells
retrieved from the CytospongeTM, which is scored in
a binary fashion, thus reducing the difficulties in diag-
nosing Barrett’s using a cytological sample. Studies
have shown that the CytospongeTM is an acceptable,
cost-effective, and relatively accurate method for diag-
nosing Barrett’s with applicability to primary care
[15,16]. This could, therefore, solve the first problem
of identifying the large proportion of individuals with
undiagnosed Barrett’s. However, the second problem
remains in terms of identifying those at increased risk
of cancer. The CytospongeTM mainly samples surface
epithelium and, although cytological atypia may be
discerned by an experienced pathologist, a conven-
tional histopathological diagnosis of dysplasia is insuf-
ficient alone as a biomarker [16].
Due to the high yield of cells from the Cytospon-
geTM this could be done as a second tier test for
patients diagnosed as TFF3 positive using the same
sample. Some data suggest that TP53 may be a use-
ful biomarker [17–21]; however, the sensitivity
(58%) and specificity (85%) of the presence of TP53
mutation in dysplastic Barrett’s CytospongeTM sam-
ples suggests that this single biomarker alone is not
suitable for routine clinical use [22]. Whilst a panel
of biomarkers may achieve a higher sensitivity {e.g.
72% when combined with p53 immunohistochemistry
(IHC) [22]}, it would be advantageous to use a single
platform. Advances in next-generation sequencing
(NGS) techniques mean that instead of focusing on a
small number of specific genes, a larger panel may
be able to capture the diversity of single nucleotide
variants (SNVs) seen in dysplasia and OAC and be
useful as a diagnostic tool [20,23]. Previous studies
have attempted to find differences between non-
dysplastic and dysplastic Barrett’s in order to aid
diagnosis but with alternative methods to NGS such
as IHC and gene expression profiling [24–26]. Gene
expression profiling is not possible due to the
formalin-fixed, paraffin-embedded (FFPE) preserva-
tion of the CytospongeTM sample which allows for a
diagnosis of Barrett’s using an immunohistochemical
assay for TFF3. Del Portillo et al showed that, by
using a cancer hot-spot panel on microdissected
FFPE Barrett’s biopsy samples, they could differenti-
ate progressors from non-progressors. Of the 10
patients with sufficient tissue, who progressed to
HGD, each had a mutation detected in their HGD
biopsy (100%) and 6/8 (75%; 7 had insufficient tis-
sue) had a mutation in their adjacent non-dysplastic
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intestinal metaplasia [27]. There were no mutations
observed in non-progressors. These observed differ-
ences prompted us to consider the potential of cou-
pling this commercial panel with the CytospongeTM
sampling device. It should be noted that microdissec-
tion is necessary because the CytospongeTM samples
a large amount of squamous epithelium in addition to
any glandular Barrett’s epithelium present.
There are certain advantages associated with the use
of a hot-spot panel that make it an appealing potential
diagnostic tool for dysplastic Barrett’s. The hot-spot
panel used in this study, the Ion AmpliSeqTM Cancer
Hotspot panel V2 (ThermoFisher Scientific, Waltham,
MA, USA), is already in clinical use and has been
fully validated. The panel uses a single pool of 207
primer pairs to perform multiplex PCR covering
>2800 mutations in 50 oncogenes and tumour sup-
pressor genes present in the Catalogue of Somatic
Mutations in Cancer (COSMIC; http://cancer.sanger.
ac.uk/cosmic): ABL1, AKT1, ALK, APC, ATM, BRAF,
CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2,
ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3,
FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, JAK2,
JAK3, IDH1, IDH2, KDR/VEGFR2, KIT, KRAS, MET,
MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA,
PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4,
SMARCB1, SMO, SRC, STK11, TP53, and VHL.
The aim of this pilot case-control study was to
determine whether dysplastic Barrett’s cases could be
distinguished from non-dysplastic Barrett’s by detect-
ing mutations using the Ion AmpliSeqTM Cancer Hot-
spot panel V2 on CytospongeTM samples.
Methods
Cohort selection
A retrospective case-control study design from recent
CytospongeTM trials was chosen to allow for a direct
comparison between patients known to have dyspla-
sia and those without. Ethical approval from the East
of England-Cambridge Ethical approval was granted
from the East of England-Cambridge Central
Research Ethics Committee (BEST2: Rec. no. 10/
H0308/71; Case1:Rec. no. 14/EE/0015). A sample
size of 30 in each group was calculated as sufficient
for this pilot experiment (a total sample size of 50
would have a power of >90% for detecting the
observed difference). Criteria for inclusion were:
clear dysplasia status and sufficient remaining tissue
(>5 gland groups) which passed sequencing quality
control. Barrett’s oesophagus of any length was
included provided that the case was TFF3 positive
(immunohistochemical marker to confirm Barrett’s
[16]) when reviewed by an expert gastrointestinal
pathologist (MO’D). Samples were excluded if the
patient did not have a surveillance endoscopy with
biopsies performed on the same day, with available
pathology. For dysplasia status, biopsies from these
endoscopies were reviewed in consensus meetings by
2–4 expert pathologists, blinded to the CytospongeTM
result. If a patient had undergone an endoscopy within
6 months prior to the CytospongeTM, and was found
to have had a higher grade at that time-point without
subsequent therapy, then this grade was assigned on
the assumption that the lesion had not been sampled
on the subsequent occasion. Follow-up data were col-
lected from our own databases and information on
progression and mortality collected from Hospital Epi-
sode Statistics (up until November 2016).
Sample preparation and sequencing
All CytospongeTM samples had been processed into
paraffin blocks as described previously [15]. The 10
3 4 mm sections of CytospongeTM tissue were cut on
to uncharged slides, with an H&E at each end. Areas
of atypia on the H&E were marked by a specialist
pathologist (MO’D). Sections were heated to 548C for
10 min and then deparaffinized in xylene for 5 min.
They were dehydrated by emersion in 99% industrial
denatured alcohol twice for 3 min each. Samples were
microdissected under a microscope by hand using a
21G needle, with the H&E as a guide, and placed in
70% ethanol (supplementary material, Figure S1).
Areas of atypia were dissected preferentially, with
additional glands taken to give an adequate DNA
yield, and the estimated % atypia was recorded. For
samples with no atypia, either all glands were dis-
sected, if there were few, or a selection of glands
from each quadrant was sampled if Barrett’s tissue
was prominent throughout the section.
An in-house, clinically validated protocol was used
for DNA extraction. Samples were warmed to 568C
for 10 min to completely evaporate the ethanol. About
7–20 ml of proteinase K digestion buffer [1 ml con-
tains: 100 ll 103 PCR buffer (Applied Biosystems,
Waltham, MA, USA; Cat. No. N8080129), 20 ml pro-
teinase K (20 mg/ml; Qiagen, Hilden, Germany; Cat.
No. 19131), 0.5 ml Nonidet P 40 (Abbott Molecular,
Des Plaines, IL, USA; Ref. No. 30–804808), 880 ml
ultrapure water was added to the sample (depending
on quantity of tissue), with a drop of mineral oil to
prevent evaporation, heated for 5 h at 568C, and dena-
tured by heating to 968C for 10 min. Quantification
was performed using the Qubit
VR
High Sensitivity
assay on the Qubit
VR
2.0 fluorometer as per the
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manufacturer’s instructions (Invitrogen, Life Technolo-
gies, Waltham, MA, USA). A minimum of 5 ng of
input DNA was required for sequencing.
Amplicon library preparation was performed using
the Ion AmpliSeqTM Library Kit 2.0 (ThermoFisher,
Waltham, MA, USA) as per the manufacturer’s proto-
col with target region amplification, amplicon partial
digestion with FuPa reagent, barcode adapter ligation,
and library purification. Libraries were quantified using
the Qubit
VR
2.0 fluorometer or using Agilent 4200
TapeStation System (Agilent Technologies, Santa
Clara, CA, USA). Sequencing was performed on the
Ion Torrent PGM platform. Sixteen samples were
loaded per chip to give an average of 10003 coverage
per amplicon. TP53 coverage was used for quality con-
trol and samples with coverage <1003 for each exon
were considered to have failed. This reflected the cov-
erage of all mutations and previous studies have con-
sidered a coverage of >1003 to be adequate [28].
Mutation analysis
Sequences were aligned to the human hg19 reference
genome and mutation calling was performed by the
Ion Torrent Suite Version 5.2. Each non-synonymous
variant call was then visually inspected in the BAM
file using the Integrated Genome Viewer version
2.3.59. Common single nucleotide polymorphisms
(SNPs) in the Single Nucleotide Polymorphism Data-
base (https://www.ncbi.nlm.nih.gov/snp) were excluded
from further analysis, if present at either 50% or 100%
of the sample, indicating them to have been inherited,
as were known false positives caused by non-specific
primer binding [29]. Where there was sufficient mate-
rial, samples were run in duplicate, with repeat library
preparation, and SNV calls were made when the muta-
tion was seen in both runs. If cases had an allele fre-
quency (AF) 12% (see Optimization of mutation
calling),> 7 base pairs from the amplicon edge and
with no strand bias >3.0 3 then these were sufficient
to call without performing a duplicate (see data in
Results for justification).
Statistical analysis
Statistical analysis was performed using Graphpad
Prism v5 (Graphpad Software Inc., La Jolla, CA,
USA). Demographics of the two groups were com-
pared using the Fisher’s exact test for sex, unpaired
Welch’s t-test for age, and Mann–Whitney U test for
other variables. Correlation was calculated using
Spearman’s rank. Differences in the mutation rate
between different dysplastic groups were compared
using the Chi-squared test. A two-tailed P value
of< 0.05 was considered significant. Sensitivity and
specificity were calculated in order to consider the
ability of the panel to diagnose dysplasia.
Results
CytospongeTM samples from 31 non-dysplastic Bar-
rett’s oesophagus and 28 dysplastic cases comprising
10 LGD, 6 HGD, 12 IMC samples met inclusion crite-
ria and yielded sequencing data using the Ion Ampli-
Seq Cancer Hotspot panel v2 on the Ion Torrent
platform (Figure 1, Table 1, supplementary material,
Table S1).
Optimization of mutation calling
First, the total numbers of non-synonymous muta-
tions were determined, as annotated by the software,
excluding known non-pathogenic SNPs. Initially, this
revealed mutations in: 13/31 non-dysplastic Barrett’s
cases with a combined total of 34 mutations and 24/
28 dysplastic cases with a total of 86 mutations. In
order to remove mutations introduced by PCR or
Figure 1. Consort diagram.
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sequencing error, more common in FFPE tissue,
BAM files were interrogated and mutations within 7
base pairs of the amplicon edge (n 5 6), those with a
strand bias >33 (n 5 7), mutations for which the
software had miscalled (n 5 1), and mutations which
were present in multiple samples in the run (n 5 1;
sequencing error) were excluded (supplementary mate-
rial, Tables S2 and S3). Previous studies using this
panel have validated a threshold of 5–10% AF (the fre-
quency of the SNV seen within the sequenced cell pop-
ulation) in fresh cell lines [28] and FFPE tissue [30].
These limits were established using the serial dilution
of pure cell lines. Singh et al [30] only reported a
mutation in a cancer at less than 10% AF if it could be
validated using another method. In our CytospongeTM
samples, we found that the high sample heterogeneity
and lower cellularity meant that it was possible for true
mutations to be present at <5% AF, which were
impossible to distinguish from false positives. In addi-
tion, it has previously been reported that a higher num-
ber of false positive mutations can occur with
decreased DNA input, poorer quality DNA, and lower
read depth [29]. This was evident in our samples.
We had 65 mutations below the 5% threshold
(after the above exclusion criteria) and therefore 10
samples were run in duplicate, with repeat library
preparation, to further define the optimal threshold.
Samples were selected to represent the variations in
AF and coverage that we were seeing, e.g. samples
with a low AF but high coverage and samples with a
high AF but low coverage. Two mutations which had
been present at 11% (likely owing to low coverage)
were not seen in the duplicate. All mutations with an
AF 12% were confirmed on repeat. Below this
threshold, it was difficult to ascertain whether a
mutation was real or not: some with low AFs< 2%
were in the duplicate. Higher coverage did not appear
to correlate with the mutation being real (supplemen-
tary material, Figure S2). Therefore, we imposed an
elevated cut-off AF of 12% for which we could be
confident of calling a mutation rather than potentially
include false positives. Duplicates were run for every
sample which called mutations with an AF< 12%
(supplementary material, Tables S2 and S3). Thus,
the final mutation status of each sample was based
on the presence of a mutation either 12%, or in
both runs if< 12%. If a duplicate run failed (n 5 1),
or the sample was not repeated because it had at least
one mutation 12% (n 5 7), then only muta-
tions 12% were included for that sample. Our
intention was to create a binary test: with sample
categorized as either mutated (contained at least one
mutation) or not mutated.
Frequency and type of mutations in non-
dysplastic and dysplastic Barrett’s
Figure 2 illustrates the mutation profile of the cohort.
Using the criteria defined above, 3/31 (9.7%) of non-
dysplastic and 20/28 (71.4%) dysplastic cases were
mutated. The median mutation rate per sample in
the non-dysplastic group was 0 (range 0–2), versus
1 (0–3) in the dysplastic group (p< 0.0001, two-tailed
Mann–Whitney U test).
TP53 was the most commonly mutated gene, as
expected, with 14/28 (50%) of the dysplastic patients
harbouring a mutation (Figure 3). CDKN2A was
mutated at 21.4% and ERBB2 at 10.7%. Another 5
genes in the panel (KRAS, APC, KDR, MET, GNAS)
were mutated at a lower frequency. In keeping with
our previous data, SMAD4 was not mutated in any
cases in the absence of invasive cancer [21]. CDKN2A
was the only gene mutated in the non-dysplastic
cohort 3/31 (9.7%) in keeping with its known loss
early in the natural history of the disease [21].
Mutation calling is not affected by the presence
or percentage of atypia, the grade of the
dysplasia or the length of the Barrett’s segment
There was a variation in the degree of atypia present
in each sample and only 19/28 dysplastic cases had
visible atypia on H&E staining. However, there was
Table 1. Demographics
Cohort demographics Non-dysplastic Dysplastic P value
No. patients 31 28
Sex – male:female 3.4:1 8.3:1 0.31††
Age years – median (range) 64 (16–81) 66.5 (51–81) 0.06†
Circumferential length Barrett’s (cm) – median (range) 1 (0–10) 4 (0–16)** 0.14*
Maximum length Barrett’s (cm) – median (range) 4 (1–11) 6 (0–17)** 0.08*
Available follow-up post-Cytosponge (months) – median (range) 50 (0–63) 41.5 (0–62) 0.11*
*Two-tailed Mann–Whitney test.
**Missing data on one patient.
†Two-tailed unpaired Welsh’s t-test.
††Two-tailed Fisher’s exact test.
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no significant difference in the total number of muta-
tions per sample in the presence or absence of atypia
(p 5 0.54), nor a correlation between the percentage
of atypia present and the total number of mutations
called (Spearman’s r 5 0.28; p 5 0.14). For two of
the cases where there was significant atypia, it was
possible to compare the calls when sequencing only
atypia versus all glands. For case M8582, KRAS and
TP53 mutations were identified in both runs but the
AF was 1.5–1.7 times higher in the sample microdis-
sected to contain atypia only. One TP53 mutation,
present at 3.4%, was not seen when all glands were
Figure 2. Histograms showing the number of mutations called in each sample (confirmed in duplicate where AF< 12%). (A) Non-
dysplastic Barrett’s. (B) Dysplastic Barrett’s.
Figure 3. Gene plot showing genes mutated in each sample. Each vertical line of boxes represents one sample.
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taken. This may be because of the lower cellularity,
or because it was not present in glands from sections
cut further along the paraffin block. Similar results
were observed for case M8583 such that the TP53
mutation AF increased from 24.6 to 46.1% with
microdissection. This suggests that, with a genetically
heterogeneous disease, microdissection is required to
increase the AF sufficiently to make a confident
mutation call even when sequencing to high depth.
There was no difference in the number of muta-
tions per sample between the different stages of dys-
plasia (10 LGD, 6 HGD, 12 IMC; p 5 0.93) or the
maximum length of the Barrett’s segment (Spear-
man’s r 5 0.40, p 5 0.002).
Sensitivity and specificity
In order to calculate the sensitivity and specificity of
the panel for diagnosing dysplasia, each sample was
categorized as being either non-mutated or mutated.
A sample was considered mutated if it had either at
least one mutation with an AF> 12%, or a mutation
at a lower AF present in duplicate.
The overall sensitivity was 71.4% (95% CI 51.3–
86.8) and specificity 90.3% (95% CI 74.3–98.0), pos-
itive predictive value 87.0% (95% CI 68.9–95.3%),
negative predictive value 77.8% (95% CI 65.8–
86.4%). This was recalculated excluding CDKN2A,
which is known to be mutated in non-dysplastic Bar-
rett’s. Whilst the specificity increased greatly to
100% (95% CI 88.8–100.0%), the sensitivity dropped
to 60.7% (95% CI 40.6–78.5%).
Patient follow-up
Follow-up data were available up to 01 November
2016 for 52 of the patients (24 dysplastic, 28 non-
dysplastic). Three patients died of unrelated causes
during the period (M9414, M9354, M9946). One of
the 28 non-dysplastic patients (M9420) progressed to
LGD in the basal crypts 6 months later but did not
have radiofrequency ablation (RFA) and further
future biopsies were non-dysplastic. Seven of the
LGD cases had follow-up data: two of which had no
mutations. One of these two cases (M9348) was
downgraded to non-dysplastic on a future endoscopy
6 months later; the other (M9340) progressed to
HGD 2.5 years later and was treated with RFA. Of
the five patients with mutations, three went on to have
RFA (M8583, MA0306), one of whom progressed to
HGD (M9858). Two (M9341, MA0362) were down-
graded to non-dysplastic status subsequently.
Discussion
We have demonstrated here that it is possible to
apply a multi-gene sequencing panel to microdis-
sected FFPE samples collected by the CytospongeTM
with the aim to distinguish non-dysplastic from dys-
plastic Barrett’s cases. In this pilot case-control
cohort, we achieved a 71.4% sensitivity and 90.3%
specificity for diagnosing dysplasia. The sensitivity
of this panel is inadequate for use as a clinical test;
however, we have shown in principle that a gene
mutation panel using NGS can distinguish the two
groups and an informed panel is likely to perform
better.
The most common mutation in the dysplastic cases
was TP53 in 50% [7/12 (58%) IMC; 3/6 (50%)
HGD; 4/10 (40%) LGD]. This rate is lower than that
seen previously in the targeted TP53 sequencing in
HGD (72%) [21] but this may be because this panel
does not sequence every exon, as discussed below.
As shown in previous literature, CDKN2A mutation
was present in 10% of non-dysplastic cases [21]. We
were unable to demonstrate the same APC mutation
rate found by del Portillo in HGD/OAC biopsies
using this panel (2/12; 17%) [27]. This is in keeping
with whole-genome and whole-exome sequencing
from the International Cancer Genome Consortium
(ICGC) and The Cancer Genome Atlas (TCGA)
which did not find APC to be significantly mutated
in this cancer [20,31]. It should be noted that we
have used the histopathological diagnosis as the gold
standard to ascertain the sensitivity and specificity of
the panel. However, lesions can be misclassified
based purely on phenotype and it is possible that the
genotype may better predict the long-term risk of
progression to OAC.
These results can be compared to a previous study
from our group in which a panel of biomarkers was
applied to CytospongeTM samples in order to stratify
patients according to the dysplasia grade (n 5 468
discovery, n 5 65 validation). TP53 mutation was
assessed along the entire gene using the Accel-
Amplicon comprehensive panel (Swift Biosciences,
NI, USA) followed by sequencing to an average of
10 000 times coverage. TP53 mutation in combina-
tion with p53 IHC [22] had a 72% sensitivity and
83% specificity for diagnosing dysplasia. When the
other parameters (atypia, aurora kinase A, clinical
parameters) were added they were able to risk stratify
patients into three groups. All patients who were
classed in the ‘low risk’ group were non-dysplastic
and, in the ‘high risk’ group, the probability of hav-
ing HGD/IMC was 87%. The AmpliSeq hot-spot
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panel used here assesses 492 positions within 7/12
TP53 exons, covering 1150 COSMIC mutations. It
gave a median sequencing depth of 1119 (interquar-
tile range 540–1889) for non-synonymous mutations
and when TP53 was considered alone gave a sensi-
tivity and specificity of 46.4 and 100%, respectively.
The AmpliSeq hot-spot panel used here informs on
the mutation status of multiple genes and has the
advantage of requiring only a single platform for use.
The whole-genome sequencing of 129 OACs by
the ICGC demonstrated that most of the genes in this
panel are mutated at a low frequency in the cancer
(1–16%; SMAD4 [16%], CDKN2A [15%]), compared
with the higher rate of TP53 mutation (81%) [20].
Other point mutated genes identified by the ICGC
whole-genome sequencing project which are not in
this hot-spot panel include: ARID1A mutated in 17%
of samples, KCNQ3 12%, and CYP7B1 7% [20]. Fur-
thermore, whole-exome sequencing of 72 OACs by
TCGA Research Network also identified recurrent
mutations in ARID1A, SMAD4, and ERBB2 [31]. The
whole-genome and whole-exome sequencing of Bar-
rett’s and cancer pairs have shown the mutational
density of SNVs in Barrett’s to be 2.8–6.76 SNVs/
Mb with mutations occurring in a number of genes
which are not in this hot-spot panel including EYS,
SYNE1, ARID1A, SMARCA4, TRIM58 [2,32]. How-
ever, the numbers of dysplastic cases in these studies
were small. Weaver et al used whole-genome
sequencing of OAC to define recurrent mutations and
then looked at their frequencies in HGD and non-
dysplastic Barrett’s with amplicon sequencing. How-
ever, the only gene which defined the boundaries of
non-dysplastic and HGD was TP53. Further analysis
of the mutation status of the above genes in dysplas-
tic Barrett’s may further inform panel design and
improve its ability to discriminate between these two
stages of pre-invasive disease. It is also known that
the copy number of genes such as ERBB2 is impor-
tant in OAC [20] but this cannot be measured accu-
rately using this AmpliSeq panel. Hoogstraat et al
have developed a custom panel, based on AmpliSeq
but with more amplicons covering fewer genes, for
which they are able to identify high-level amplifica-
tions at a 25% cell-line dilution by considering devia-
tions in depth of coverage [33]. This might be
interesting to explore in the future given the high-
level amplifications seen in this cancer [20,34,35].
The CytospongeTM sample has the advantage over
analysing a single biopsy because it takes a sweep
from along the entire oesophagus and it has been
shown to sample every clone in the Barrett’s seg-
ment [2]. However, the disadvantage of this is that the
Barrett’s segment is genetically very heterogeneous and
most mutations will be present at a low AF. The sam-
ples are also formalin-fixed and paraffin-embedded.
Whilst this is a standard clinical method for sample
preparation, the DNA is fragmented and more diffi-
cult to sequence and C>T false calls are more
likely. In the future, treating FFPE DNA with uracil
glycolase to remove these cytosine deamination-
induced changes could minimize this. During the
amplification stages of library preparation, there is
the potential for introducing mutations, which would
similarly be the case if frozen tissue was used. These
factors led us to sequence at high depth (10003) and
great care was taken in defining the cut-off for call-
ing a mutation. Previous studies have found that
mutations can accurately be called if they have an
AF of 5% or greater [28]. The lowest AF mutation
which we confirmed was present at 1.7%. However,
of the 54 mutations below 5% which were run in
duplicate (excluding those which had previously met
exclusion criteria) only 6 (11%) were present in the
repeat (supplementary material, Tables S2 and S3).
This meant that in order to call the low frequency
mutations confidently, duplicates were needed, mak-
ing this impractical and expensive as a clinical test
for Barrett’s oesophagus. The new methods of library
preparation which use molecular barcoding could
overcome this problem because they facilitate the
accurate calling of SNVs down to an AF of 1%.
Caution is advised for generalizing the results of
this study. Samples were chosen carefully for inclu-
sion such that those with fewer than five gland
groups or TFF3 negative were excluded and 13.9%
(10/72) of samples failed library prep or sequencing
(supplementary material, Table S4) so the true sensi-
tivity and specificity could be lower. Using newer
samples may possibly overcome some of the difficul-
ties we faced with failure of sequencing in archival
samples and microdissecting more sections would
increase yield. One of the strengths of this study was
that all the techniques and protocols used are cur-
rently used in the clinic. However, microdissection is
a time-consuming method of improving cellularity.
Whilst it is used clinically for the molecular typing
of solid tumours, the areas of interest are usually
confined to one area of the tumour so the microdis-
section is faster. In this study, between 1 and 60% of
the whole section were microdissected (median 10%)
and so mutations at low allele frequencies would not
be seen if the whole section had been extracted.
Overall, while this approach is technically feasible
for CytospongeTM samples, the generic cancer hot-
spot panel alone is unable to diagnose Barrett’s dys-
plasia with a high enough sensitivity to be a useful
clinical test. A custom panel in combination with
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alternative types of marker has the potential to accu-
rately risk stratify Barrett’s when used in combina-
tion with biopsy or cell collection devices in the
future.
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SUPPLEMENTARY MATERIAL ONLINE
Figure S1. CytospongeTM microdissection. 38 magnification. H&Es are used to guide microdissection of the unstained sections. Areas for dis-
section are indicated in black with atypical areas marked
Figure S2. The difficulty with calling mutations. Sample M9346 had 8 mutations called in the first run of which none of them were seen in
the duplicate. The PIK3CA mutation has a high allele frequency (AF) of 11%, and despite the lower coverage of 300, this looked real on
inspection of the BAM file in IGV (A). Sample M9796 had all three mutations confirmed in the repeat despite the low AFs. The ERBB2 muta-
tion was 10 base pairs from the edge of the amplicon in a noisy part of the genome as shown in the IGV screen shot (B)
Table S1. Microdissection and extraction information for the cohort
Table S2. All mutations called for each non-dysplastic sample and duplicate. Mutations highlighted in grey were used in final calls
Table S3. All mutations called for each dysplastic sample and duplicate. Mutations highlighted in grey were used in final calls
Table S4. Samples that failed library preparation/sequencing
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